Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys

Abstract

Aims/hypothesis. We examined risk factor management in diabetic and non-diabetic patients with CHD based on data from EUROASPIRE surveys. Methods. Consecutive CHD patients aged 70 years or younger were interviewed and examined at least 6 months after hospitalisation for a revascularisation procedure or acute myocardial infarction or ischaemia. Of these patients, 3569 were from the EUROASPIRE I study, undertaken from 1995 to 1996 in nine countries, and 5556 were from the EUROASPIRE II study, conducted between 1999 and 2000 in 15 countries. Results. In EUROASPIRE I and II 18% and 20% of CHD patients respectively had been previously diagnosed with diabetes. Fasting glucose screening raised the prevalence of diabetes in EUROASPIRE II to 28%. In EUROSPIRE II the prevalence of risk factors (known diabetic/non-diabetic) was: current smoking 17%/22 % (p=0.25); obesity (BMI ≥30 kg/m 2 ) 43%/ 29% (p<0.001); raised blood pressure (≥140/90 mm Hg) 57%/49% (p<0.001); and elevated total cholesterol (≥5.0 mmol/l) 55%/59% (p<0.001). The proportion of users of cardiovascular medication was: antiplatelet drugs 83%/86% (NS); beta-blockers 62%/63% (NS); ACE inhibitors 49%/35% (p<0.001); and lipid-lowering drugs 62%/61% (NS). A comparison of both studies showed that for diabetic and non-diabetic patients the prevalence of smoking had increased somewhat and that the prevalence of obesity had increased clearly. There was no improvement in blood pressure control, but cholesterol control had improved, mainly explained by the increased use of lipid-lowering drugs. Conclusions/interpretation. These European surveys show a high prevalence of adverse lifestyles and modifiable risk factors among diabetic and non-diabetic patients with CHD. The risk factor status was more adverse in diabetic patients.

Serum Zinc Level and Coronary Heart Disease Events in Patients With Type 2 Diabetes

“…Today ϳ50% of type 2 diabetic patients use statins, which are known to prevent CHD events effectively (33,34). It would be interesting to study whether low serum zinc level also predicts CHD events in the statin era.…”

Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2

“…In the NCEP Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II, a US national survey undertaken in 2003, achievement of NCEP ATP III LDL cholesterol success in patients with diabetes and no CHD was 55%, compared with 62% in patients with CHD and no diabetes, indicating that diabetes was being undertreated as a CHD risk equivalent 23 . The earlier EUROASPIRE II study, conducted in 1999-2000, reported lower attainment of LDL cholesterol 597 mg/dl (2.5 mmol/l) in patients with CHD and no diabetes, compared with patients who had both diabetes and CHD (21% vs. 25%) 24 .…”

Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants

“…Importantly, only 12% of our study patients were known as diabetics while an elevated HbA 1c level was detected in another 16% of patients who were not known with diabetes. These findings underscore again the importance of active screening for diabetes which is a strong risk factor for a worse clinical outcome in patients with CAD [21].…”